The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
This review considers the use of the first selective blocker of the cannabinoid receptor type 1, rimonabant, to reduce weight and improve cardiovascular disease risk factors in obese patients with metabolic syndrome or multiple cardiovascular disease risk factors. In 4 large trials—Rimonabant in Obesity (RIO)–Lipids, RIO‐Europe, RIO–North America, and RIO‐Diabetes—after 1 to 2 years of treatment, rimonabant (20 mg/day) led to a significantly greater weight loss and reduction in waist circumference compared with placebo. Treatment with rimonabant was also associated with other favorable changes, including better glycemic control in type 2 diabetes mellitus, improved lipid profile, reduced blood pressure, increased adiponectin levels, fall in high‐sensitivity C‐reactive protein concentrations, and an overall decrease in the prevalence of the metabolic syndrome. Initial experience with rimonabant shows that it is generally well tolerated with the most common side effect of mild nausea. Rimonabant may be a useful adjunct to lifestyle and behavior modification in the treatment of obese subjects with metabolic syndrome or multiple cardiometabolic risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
Ridker, P. M., Buring, J. E., Cook, N. R., & Rifai, N. (2003) · Circulation · doi:10.1161/01.cir.0000055014.62083.05 · Cited by 2,292
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Activation of the EC system promotes food ingestion, relaxation, pain reduction, and the extinction of aversive memories.(21,22) The endogenous cannabinoids exert their pharmacologic action through interaction with the specific receptors, CB1 and CB2.”
BackgroundRoss, R., Dagnone, D., Jones, P. J. H., Smith, H., Paddags, A., Hudson, R., & Janssen, I. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00008 · Cited by 1,435 · cited 3×
“As compared with placebo, rimonabant at a dose of 20 mg per day induced significant weight loss and reduction in waist circumference, suggesting a substantial mobilization of abdominal fat, which, by itself, would predict an improved CVD risk profile, including HDL-C.(50) Plasma leptin is produced by adipose tissue an…”
InfluentialAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 1×
“007), thus inducing a less atherogenic LDL profile.(77) Plasma LDL-C levels are the main target for treatment in lipid guidelines.”
BackgroundEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 6×
“6% in RIO-NA(44) to 50% in the RIO-Europe study (2-year results(43)) and 52% in RIO-Lipids.(41)”
BackgroundInfluentialEndothelial dysfunction in diabetes
De Vriese, A. S., Verbeuren, T. J., Van de Voorde, J., Lameire, N. H., & Vanhoutte, P. M. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703393 · Cited by 1,165 · cited 2×
“These end products are responsible for a range of effects, including quenching nitric oxide and contributing to oxidative stress and inflammatory processes.(84,85) Glycation end products, which undergo receptor-mediated endocytosis into vascular ROLE OF ENDOCANNABINOID SYSTEM BLOCKADE”
BackgroundLaaksonen, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf145 · Cited by 916
Assmann, G., & Schulte, H. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90550-i · Cited by 872
Rutter, M. K., Meigs, J. B., Sullivan, L. M., D’Agostino, R. B., & Wilson, P. W. F. (2004) · Circulation · doi:10.1161/01.cir.0000136581.59584.0e · Cited by 664
Cited by
Exercise, Vascular Wall and Cardiovascular Diseases: An Update (Part 1)
Leung, F. P., Yung, L. M., Laher, I., Yao, X., Chen, Z. Y., & Huang, Y. (2008) · Sports Medicine · doi:10.2165/00007256-200838120-00005 · Cited by 219
Cardiovascular benefits of bariatric surgery in morbidly obese patients
Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00831.x · Cited by 94
Self-citationExercise, Vascular Wall and Cardiovascular Diseases: An Update (Part 2)
Yung, L. M., Laher, I., Yao, X., Chen, Z. Y., Huang, Y., & Leung, F. P. (2009) · Sports Medicine · doi:10.2165/00007256-200939010-00004 · Cited by 93
The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity
Paspala, I., Katsiki, N., Kapoukranidou, D., Mikhailidis, D. P., & Tsiligiroglou-Fachantidou, A. (2012) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401206010147 · Cited by 18
Self-citation
Metadata
- Authors
- Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A., & Athyros, V. G.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2007-05
- Volume
- 47
- Issue
- 5
- Pages
- 642-652
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2115057047
- Cited by
- 39
- References
- 16
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. https://app.cochat.ai/papers/10.1177/0091270007299358
- The paper
- Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A., & Athyros, V. G. (2007). The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270007299358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.